J B Chemicals & Pharmaceuticals Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cts7rwpzz5t3aju8eid8jpw8.pdf

Key Takeaways


Domestic Business: Chronic Strength, Acute Softness

Kunal Khanna: “No. So no real concern with the overall growth for domestic business. Our chronic portfolio has done exceedingly well. And the 1%, 1.5% difference, which we are seeing, instead of that 11% to 12%, being closer to 10% is largely attributed to some slowdown for our acute business, more specifically the gastro portfolio.”

International Formulations: Order-Book Execution Drove the Beat


CDMO: Flat Against a High Base, Growth Ahead

Nikhil Chopra: “Our run rate for the quarter -- for every quarter continues to be around INR115 crore to INR120 crore for this year. And you should expect us to grow at around 10% to 12% for FY '27.”

Margins: Mix and Efficiency Drove the Expansion


Merger & Capital Allocation: Torrent Deal in Q4, Dividend Paused


Guidance & Commitments

CommitmentSpecificsTimeline
Operating margin27% to 29% bandFY26
Gross marginReach 68% to 69%By FY26 year-end
Domestic growth200-300 bps above IPM market growthOngoing; Q4 FY26
International business growthHigh single digitFull year FY26
CDMO growth10% to 12%FY27
Ophthalmology monthly run rateINR17-18 croreNext 3-4 months
Torrent merger deal closureDeal closure expectedQ4 FY26

Key Metrics

MetricQ3 FY26
Revenue₹1,065 crore, up 11% YoY
Domestic revenue₹620 crore, up 10% YoY
International revenue₹445 crore, up 12% YoY
International formulations revenue₹306 crore, up 20% YoY
CDMO revenue₹117 crore, nearly flat YoY
API revenue₹21 crore
Domestic franchisee revenue₹108 crore, up 11% YoY
Gross margin69.1%, up 200 bps YoY from 67.1%
Operating EBITDA (excl. ESOP)₹305 crore, up 13% YoY
Operating EBITDA margin28.7%, up 60 bps YoY from 28.1%
Net profit₹198 crore, up 22% YoY
Other income₹18 crore, up from ₹8 crore in Q3 FY25 due to treasury income
Depreciation₹45 crore, up from ₹42 crore in Q3 FY25
Domestic price hike~7% for the quarter
Company IPM growth (IQVIA MAT Dec 2025)12%, versus IPM growth of 9%
CDMO quarterly run rate₹115 crore to ₹120 crore for FY26
CDMO FY27 growth expectation10% to 12%
Ophthalmology portfolio monthly run rate aspiration₹17 crore to ₹18 crore, expected in next 3 to 4 months
ESOP charge if change of control occurs in Q4~₹40 crore balance to be charged in Q4
Operating margin guidance for FY2627% to 29%, reiterated
India business Q4 FY26 growth guidance200 to 300 bps above market growth
Gross margin guidance for Q4 FY2660% to 69% by year-end